Scarica l'app Stockscreener
11.02
13.23%
-1.68
Dopo l'orario di chiusura:
11.00
-0.02
-0.18%
Precedente Chiudi:
$12.70
Aprire:
$12.8
Volume 24 ore:
801.47K
Relative Volume:
4.64
Capitalizzazione di mercato:
$554.55M
Reddito:
$31.37M
Utile/perdita netta:
$-53.77M
Rapporto P/E:
-7.7431
EPS:
-1.4232
Flusso di cassa netto:
$-49.02M
1 W Prestazione:
-37.17%
1M Prestazione:
-38.74%
6M Prestazione:
-52.09%
1 anno Prestazione:
+21.10%
Intervallo 1D:
$10.86
$12.80
Intervallo di 1 settimana:
$10.86
$17.50
Portata 52W:
$9.22
$27.72
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Nome
Silence Therapeutics Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta SLN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| SLN | 11.02 | 554.55M | 31.37M | -53.77M | -49.02M | -1.4232 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Silence Therapeutics Plc Adr Borsa (SLN) Ultime notizie
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine - Investing.com
It makes sense and dollars to buy Silence Therapeutics Plc ADR (SLN) stock - SETE News
Silence Therapeutics Plc ADR (SLN) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
What Did We Find About Insider Trading At Silence Therapeutics Plc ADR (NASDAQ: SLN)? - Stocks Register
Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data - Investing.com UK
H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results By Investing.com - Investing.com South Africa
How did Silence Therapeutics Plc ADR (SLN) fare last session? - US Post News
Ratio Revelations: Silence Therapeutics Plc ADR (SLN)’s Financial Metrics in the Spotlight - The Dwinnex
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny - US Post News
Market Insight: Silence Therapeutics Plc ADR (SLN)’s Notable Drop, Closing at 16.70 - The Dwinnex
It would be worthwhile to take a closer look at Silence Therapeutics Plc ADR (SLN) - US Post News
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? - Yahoo Finance
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny – US Post News - US Post News
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com India
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics - Yahoo Lifestyle UK
Hardman & Co Insight: Survival of the UK life sciences sector - Research Tree
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Altria maintains stock target, Buy rating on FDA move By Investing.com - Investing.com UK
Zerlasiran shows promise in phase 2 study for cardiovascular risk By Investing.com - Investing.com
Is Silence Therapeutics Plc ADR (SLN) a good investment opportunity? – US Post News - US Post News
Trading Day Triumph: Silence Therapeutics Plc ADR (SLN) Ends at 21.54, a -2.49 Surge/Plunge – DWinneX - The Dwinnex
European Equities Traded in the US as American Depositary Receipts Start Week Off Lower Monday - MSN
Kirby Corp CEO sells shares worth over $360k By Investing.com - Investing.com
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
BMO maintains $67 stock target on Silence Therapeutics stock By Investing.com - Investing.com UK
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Yahoo Finance
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy - Yahoo Finance UK
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect? - Yahoo Finance
Wall Street Analysts Predict a 361.54% Upside in Silence Therapeutics PLC Sponsored ADR (SLN): Here's What You ... - Yahoo Finance UK
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Yahoo Canada Finance
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues - Benzinga
The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO - Benzinga
The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping - Yahoo Finance
The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation - Yahoo Finance
The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca's Breakthrough Therapy Designation, 3 IPOs - Yahoo Finance
Silence Therapeutics A Quieter Name In RNAi (NASDAQ:SLN) - Seeking Alpha
Silence Therapeutics Plc Adr Azioni (SLN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):